January 11, 2023
AstraZeneca and Ono Pharmaceutical said on January 10 that they have won a label update from Japanese regulators for their SGLT2 inhibitor Forxiga (dapagliflozin), which allows the drug’s use for chronic heart failure, irrespective of left ventricular ejection fraction (LVEF)...read more